{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T06:30:03Z","timestamp":1791095403794,"version":"4.1.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,11,12]]},"DOI":"10.1097\/qad.0b013e328315a7a5","type":"journal-article","created":{"date-parts":[[2008,10,31]],"date-time":"2008-10-31T03:09:42Z","timestamp":1225422582000},"page":"2313-2321","source":"Crossref","is-referenced-by-count":31,"title":["Effects of boosted tipranavir and lopinavir on body composition, insulin sensitivity and adipocytokines in antiretroviral-naive adults"],"prefix":"10.1097","volume":"22","author":[{"given":"Andrew","family":"Carr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Ritzhaupt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Zajdenverg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassy","family":"Workman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose M","family":"Gatell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Cahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Chaves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-10-20210130","doi-asserted-by":"crossref","first-page":"F51","DOI":"10.1097\/00002030-199807000-00003","article-title":"A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors","volume":"12","author":"Carr","year":"1998","journal-title":"AIDS"},{"key":"R2-10-20210130","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1056\/NEJMra041811","article-title":"Cardiovascular risk and body fat abnormalities in HIV-infected adults","volume":"352","author":"Grinspoon","year":"2005","journal-title":"N Engl J Med"},{"key":"R3-10-20210130","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1097\/00002030-200305020-00005","article-title":"Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy","volume":"17","author":"Mallon","year":"2003","journal-title":"AIDS"},{"key":"R4-10-20210130","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.2337\/diabetes.50.6.1378","article-title":"The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance","volume":"50","author":"Caron","year":"2001","journal-title":"Diabetes"},{"key":"R5-10-20210130","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/oby.2006.114","article-title":"HIV protease inhibitor-specific alterations in human adipocyte differentiation and metabolism","volume":"14","author":"Kim","year":"2006","journal-title":"Obesity"},{"key":"R6-10-20210130","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1177\/135965350501000202","article-title":"Altered adipokine response in murine 3T3-F442A adipocytes treated with protease inhibitors and nucleoside reverse transcriptase inhibitors","volume":"10","author":"Jones","year":"2005","journal-title":"Antivir Ther"},{"key":"R8-10-20210130","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1097\/01.aids.0000183629.20041.bb","article-title":"Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides","volume":"19","author":"Dub\u00e9","year":"2005","journal-title":"AIDS"},{"key":"R9-10-20210130","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1086\/498505","article-title":"Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients","volume":"42","author":"Jemsek","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R11-10-20210130","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1097\/00002030-200109280-00010","article-title":"HIV protease inhibitor substitution in patients with lipodystrophy: a randomised, multicentre, open-label study","volume":"15","author":"Carr","year":"2001","journal-title":"AIDS"},{"key":"R12-10-20210130","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1086\/505974","article-title":"Single-dose lopinavir-ritonavir acutely inhibits insulin-mediated glucose disposal in healthy volunteers","volume":"43","author":"Lee","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R13-10-20210130","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1097\/01.aids.0000244200.11006.55","article-title":"Effects of atazanavir\/ritonavir and lopinavir\/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically","volume":"20","author":"Noor","year":"2006","journal-title":"AIDS"},{"key":"R14-10-20210130","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/135965350300800102","article-title":"Adipocyte-derived hormone levels in HIV lipodystrophy","volume":"8","author":"Kosmiski","year":"2003","journal-title":"Antiviral Ther"},{"key":"R15-10-20210130","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1365-2362.2004.01379.x","article-title":"Serum adiponectin and metabolic parameters in HIV-I-infected patients after substitution of nevirapine for protease inhibitors","volume":"34","author":"Petit","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"R16-10-20210130","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1365-2249.2004.02367.x","article-title":"Low plasma level of adiponectin is associated with stavudine treatment and lipodystrophy in HIV-infected patients","volume":"135","author":"Lindegaard","year":"2004","journal-title":"Clin Exp Immunol"},{"key":"R17-10-20210130","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2337\/dc06-1075","article-title":"Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein and hypoadiponectinemia","volume":"30","author":"Samaras","year":"2007","journal-title":"Diabetes Care"},{"key":"R18-10-20210130","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1097\/00126334-200405010-00017","article-title":"HIV protease inhibitors increase adiponectin levels in HIV-negative men","volume":"36","author":"Lee","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R20-10-20210130","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","article-title":"Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial","volume":"292","author":"Gallant","year":"2004","journal-title":"JAMA"},{"key":"R21-10-20210130","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/01.qai.0000245886.51262.67","article-title":"Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine\/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes: a 96-week analysis","volume":"43","author":"Pozniak","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R22-10-20210130","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/00126334-200308150-00004","article-title":"An objective lipodystrophy severity grading scale using the lipodystrophy case definition score","volume":"33","author":"Carr","year":"2003","journal-title":"J Acquir Immun Defic Syndr"},{"key":"R23-10-20210130","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"R25-10-20210130","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1080\/01621459.1987.10478478","article-title":"Sample size determination for some common nonparametric tests","volume":"82","author":"Noether","year":"1987","journal-title":"J Am Stat Association"},{"key":"R30-10-20210130","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1097\/00002030-200011100-00007","article-title":"Ritonavir increases the level of active ADD-1\/SREBP-1 protein during adipogenesis","volume":"14","author":"Nguyen","year":"2000","journal-title":"AIDS"},{"key":"R33-10-20210130","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1007\/s00125-005-0085-3","article-title":"In treatment-na\u00efve and antiretroviral-treated subjects with HIV, reduced plasma adiponectin is associated with a reduced fractional clearance rate of VLDL, IDL and LDL apolipoprotein B-100","volume":"49","author":"Das","year":"2006","journal-title":"Diabetologia"},{"key":"R34-10-20210130","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/00126334-200212150-00009","article-title":"Adiponectin and leptin levels in HIV-infected subjects with insulin resistance and body fat redistribution","volume":"31","author":"Mynarcik","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R35-10-20210130","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1210\/en.2003-1140","article-title":"Adiponectin ameliorates dyslipidemia induced by the human immunodeficiency virus protease inhibitor ritonavir in mice","volume":"145","author":"Xu","year":"2004","journal-title":"Endocrinology"},{"key":"R36-10-20210130","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa062744","article-title":"Class of antiretroviral drug and the risk of myocardial infarction.","volume":"356","year":"2007","journal-title":"N Engl J Med"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/QAD.0b013e328315a7a5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:14:15Z","timestamp":1786036455000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002030-200811120-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11,12]]},"references-count":26,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/qad.0b013e328315a7a5","relation":{},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2008,11,12]]}}}